These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 20002666

  • 21. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):983-9. PubMed ID: 19409726
    [Abstract] [Full Text] [Related]

  • 22. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1009-16. PubMed ID: 18963539
    [Abstract] [Full Text] [Related]

  • 23. Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy.
    Murota-Kawano A, Nakano M, Hongo S, Shoji S, Nagata Y, Uchida T.
    BJU Int; 2010 Jun 15; 105(12):1642-5. PubMed ID: 19922544
    [Abstract] [Full Text] [Related]

  • 24. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May 15; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 25. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 26. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D, Cowan J, Carroll P, Konety B.
    BJU Int; 2010 Apr 15; 105(7):951-5. PubMed ID: 19889066
    [Abstract] [Full Text] [Related]

  • 27. Salvage radiotherapy for biochemical recurrence after radical prostatectomy.
    Terai A, Matsui Y, Yoshimura K, Arai Y, Dodo Y.
    BJU Int; 2005 Nov 15; 96(7):1009-13. PubMed ID: 16225518
    [Abstract] [Full Text] [Related]

  • 28. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK.
    Urology; 2004 Jul 15; 64(1):84-9. PubMed ID: 15245941
    [Abstract] [Full Text] [Related]

  • 29. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov 15; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

  • 30. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
    Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y.
    Prostate; 2004 Feb 15; 58(3):269-76. PubMed ID: 14743466
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
    Patel R, Lepor H, Thiel RP, Taneja SS.
    Urology; 2005 May 15; 65(5):942-6. PubMed ID: 15882728
    [Abstract] [Full Text] [Related]

  • 33. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D.
    J Urol; 2004 Mar 15; 171(3):1141-7. PubMed ID: 14767288
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM.
    Urology; 2007 Oct 15; 70(4):723-7. PubMed ID: 17991544
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.